曲美替尼联合多西他赛或培美曲塞治疗晚期非小细胞肺癌的1/1b期研究
这项1/1b期研究评估曲美替尼联合多西他赛或培美曲塞在晚期非小细胞肺癌患者中的安全性、耐受性、药代动力学和疗效。两种联合方案的总缓解率均达到主要终点,在KRAS突变型非小细胞肺癌中观察到超过既往多西他赛或培美曲塞单药报告的缓解率,且不良事件可控。
要点
- 曲美替尼联合多西他赛组47例中10例(21%)确认部分缓解。
- 曲美替尼联合培美曲塞组42例中6例(14%)部分缓解。
- 联合方案不良事件最常见为腹泻、恶心和乏力,总体可控。
核心结论
- 曲美替尼联合化疗方案耐受性良好,在KRAS突变型非小细胞肺癌中观察到超过既往多西他赛或培美曲塞单药报告的客观缓解率,并达到预设标准。
研究设计与样本
- 1/1b期研究,第1b部分评估曲美替尼联合多西他赛(联合生长因子支持)或培美曲塞在晚期非小细胞肺癌患者中的安全性、耐受性、药代动力学和疗效。
- 扩展队列入组标准为转移性非小细胞肺癌、有可测量病灶、已知KRAS突变状态、美国东部肿瘤协作组体能状态评分≤1、既往治疗方案不超过两种。
主要发现
- 曲美替尼联合多西他赛组47例中10例确认部分缓解,客观缓解率21%。
- 曲美替尼联合多西他赛组KRAS野生型22例中4例部分缓解,客观缓解率18%;KRAS突变型25例中6例部分缓解,客观缓解率24%。
- 曲美替尼联合培美曲塞组42例中6例部分缓解,客观缓解率14%。
- 曲美替尼联合培美曲塞组KRAS突变型23例中4例部分缓解,客观缓解率17%;KRAS野生型19例中2例部分缓解,客观缓解率11%。
- 不良事件最常见为腹泻、恶心和乏力,总体可控。
关键数值与推荐
- 曲美替尼联合多西他赛方案:曲美替尼2.0 mg每日一次,多西他赛75 mg/m2每3周一次,联合生长因子支持。
- 曲美替尼联合培美曲塞方案:曲美替尼1.5 mg每日一次,培美曲塞500 mg/m2每3周一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This two-part study evaluated trametinib, a MEK1/2 inhibitor, in combination with anticancer agents. Inhibition of MEK, a downstream effector of KRAS, demonstrated preclinical synergy with chemotherapy in KRAS-mutant NSCLC cell lines. Part 1 of this study identified recommended phase 2 doses of trametinib combinations. Part 2, reported herein, evaluated the safety, tolerability, pharmacokinetics, and efficacy of trametinib combinations in patients with NSCLC with and without KRAS mutations. METHODS: Phase 1b evaluated trametinib plus docetaxel with growth factor support (trametinib, 2.0 mg once daily, and docetaxel, 75 mg/m2 every 3 weeks) or pemetrexed (trametinib, 1.5 mg once daily, and pemetrexed, 500 mg/m2 every 3 weeks). Eligibility criteria for the expansion cohorts included metastatic NSCLC with measurable disease, known KRAS mutation status, Eastern Cooperative Oncology Group performance status of 1 or lower, and no more than two prior regimens. RESULTS: The primary end point of overall response rate (ORR) was met for both combinations. A confirmed partial response (PR) was observed in 10 of the 47 patients with NSCLC who received trametinib plus docetaxel (21%). The ORR was 18% (four PRs in 22 patients) in those with KRAS wild-type NSCLC versus 24% (six PRs in 25 patients) in those with KRAS-mutant NSCLC. Of the 42 patients with NSCLC treated with trametinib plus pemetrexed, six (14%) had a PR; the ORR was 17% (four of 23) in patients with KRAS-mutated NSCLC versus 11% (two of 19) in KRAS wild-type NSCLC. Adverse events-most commonly diarrhea, nausea, and fatigue-were manageable. CONCLUSIONS: Trametinib-plus-chemotherapy combinations were tolerable. Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed.
引用
- Gandara DR, Leighl N, Delord JP, et al. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2016. PMID: 27876675. doi:10.1016/j.jtho.2016.11.2218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。